NR4A1 and breast cancer: To date no nationwide, prospective, multicenter study has been available in China to evaluate the QoL of postmenopausal patients with early-stage breast cancer (EBC) positive (+) for hormone receptors (HR) treated with adjuvant therapy with AIs.